Results 201 to 210 of about 817,145 (264)

Incorporating patients' input in the development and validation of patient-reported outcome measures in oncology: a comprehensive scoping review. [PDF]

Health Qual Life Outcomes
Shakhnenko I, Hovsepyan S, Holthuis EI, Bulbeck H, van der Graaf WTA, Husson O.   +5 more
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Integration of Patient-Reported Outcome Measures in Clinical Practice for Head and Neck Cancer Patients: A Cross-Sectional Survey. [PDF]

Curr Oncol
Dragan T, Hubel N, Lehmann J, Taylor KJ, Bultijnck R, Gašpert T, Lorini L, Bourbonne V, Beddok A, Tomasik B, Nevens D, Cavalieri S, Gómez RGH, Looman EL, Zsuzsanna IE, Kraja F, Lidington E, Lengyel CG, Oliva M, Petruzzi G, Gomes AV, Hernandez MPS, Zanten SVV, Brenes Castro J, Caparrotti F, Fanetti G, Eller YG, Gottardi C, Wishart LR, Szturz P.   +29 more
europepmc   +1 more source

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

Molecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park, Kyongman An, Gyeonghwa Kim, Soo‐Nyun Choi, Hong‐Ki Lee, Keun Hur, Kyu‐Shik Jeong   +6 more
wiley   +1 more source

Use of Parent- and Patient-Reported Outcome Measures in Pediatric Specialty Clinics: A Pilot Randomized Clinical Trial. [PDF]

JAMA Netw Open
Jones R, Devlin N, McLean K, Roberts G, Berry A, Shanthikumar S, Trajanovska M, King S, Hiscock H, Dalziel KM.   +9 more
europepmc   +1 more source

Astrocyte heterogeneity in brain metastases

Molecular Oncology, EarlyView.
Astrocytes emerge as pivotal regulators of metastatic colonization, survival, immune remodeling, and therapy response associated with an increasing heterogeneity that requires spatially and longitudinally resolved approaches to uncover regulatory programs and guide context‐specific therapies.
Carolina Hernández‐Oliver, Neibla Priego, Manuel Valiente   +2 more
wiley   +1 more source

Variation in the feasibility and acceptability of electronic patient-reported outcome measures in patients with inflammatory arthritis. [PDF]

Rheumatol Adv Pract
Cox N, Kettle C, Wang H, Dutta S, Packham J, Galloway J, Hill J, Muller S, Hider S, Paskins Z, Bullock L, Scott IC.   +11 more
europepmc   +1 more source

Patient-Reported Outcome Measures Help Patients With Cancer

JAMA Network Open
Michael J, Hassett, Christine, Cronin
openaire   +2 more sources

Preoperative circulating tumor cells integrated with imaging analysis for prognostic evaluation in head and neck squamous cell carcinoma

Molecular Oncology, EarlyView.
Detecting circulating tumor cells (CTCs) in blood before surgery may help predict outcomes in patients with head and neck squamous cell carcinoma (HNSCC). Here, we show when combined with tumor size and lymph node involvement from routine imaging, CTC status identifies high‐risk patients with poorer survival—offering a simple, minimally invasive tool ...
Susanne Flach, Gizem Abaci, Tom Huberty, Axel Lechner, Lukas Käsmann, Jens Ricke, Sophia Stöcklein, Martin Canis, Philipp Baumeister, Marianna Alunni‐Fabbroni   +9 more
wiley   +1 more source